nodes	percent_of_prediction	percent_of_DWPC	metapath
Dabrafenib—SLCO1B1—Penicillamine—rheumatoid arthritis	0.205	0.297	CbGbCtD
Dabrafenib—ABCG2—Leflunomide—rheumatoid arthritis	0.0512	0.0743	CbGbCtD
Dabrafenib—SLCO1B1—Sulfasalazine—rheumatoid arthritis	0.0398	0.0578	CbGbCtD
Dabrafenib—ABCG2—Sulfasalazine—rheumatoid arthritis	0.0316	0.0459	CbGbCtD
Dabrafenib—SLCO1B1—Cyclosporine—rheumatoid arthritis	0.0302	0.0438	CbGbCtD
Dabrafenib—SLCO1B3—Methotrexate—rheumatoid arthritis	0.0274	0.0398	CbGbCtD
Dabrafenib—ABCG2—Hydrocortisone—rheumatoid arthritis	0.0254	0.0369	CbGbCtD
Dabrafenib—ABCG2—Cyclosporine—rheumatoid arthritis	0.024	0.0348	CbGbCtD
Dabrafenib—SLC22A6—Cyclosporine—rheumatoid arthritis	0.0194	0.0282	CbGbCtD
Dabrafenib—SLCO1B1—Methotrexate—rheumatoid arthritis	0.016	0.0232	CbGbCtD
Dabrafenib—ABCG2—Dexamethasone—rheumatoid arthritis	0.0158	0.0229	CbGbCtD
Dabrafenib—ABCB1—Methylprednisolone—rheumatoid arthritis	0.015	0.0219	CbGbCtD
Dabrafenib—SLC22A8—Methotrexate—rheumatoid arthritis	0.0147	0.0214	CbGbCtD
Dabrafenib—CYP2C8—Hydrocortisone—rheumatoid arthritis	0.0135	0.0196	CbGbCtD
Dabrafenib—CYP2C8—Cyclosporine—rheumatoid arthritis	0.0128	0.0185	CbGbCtD
Dabrafenib—ABCG2—Methotrexate—rheumatoid arthritis	0.0127	0.0184	CbGbCtD
Dabrafenib—CYP3A4—Ergocalciferol—rheumatoid arthritis	0.0122	0.0178	CbGbCtD
Dabrafenib—SLC22A6—Methotrexate—rheumatoid arthritis	0.0103	0.0149	CbGbCtD
Dabrafenib—ABCB1—Betamethasone—rheumatoid arthritis	0.00978	0.0142	CbGbCtD
Dabrafenib—ABCB1—Prednisolone—rheumatoid arthritis	0.00965	0.014	CbGbCtD
Dabrafenib—ABCB1—Hydrocortisone—rheumatoid arthritis	0.00915	0.0133	CbGbCtD
Dabrafenib—ABCB1—Prednisone—rheumatoid arthritis	0.00911	0.0132	CbGbCtD
Dabrafenib—CYP3A4—Methylprednisolone—rheumatoid arthritis	0.00901	0.0131	CbGbCtD
Dabrafenib—ABCB1—Cyclosporine—rheumatoid arthritis	0.00864	0.0126	CbGbCtD
Dabrafenib—CYP2C8—Dexamethasone—rheumatoid arthritis	0.0084	0.0122	CbGbCtD
Dabrafenib—CYP3A4—Triamcinolone—rheumatoid arthritis	0.00683	0.00992	CbGbCtD
Dabrafenib—CYP3A4—Betamethasone—rheumatoid arthritis	0.00586	0.00851	CbGbCtD
Dabrafenib—CYP3A4—Prednisolone—rheumatoid arthritis	0.00578	0.0084	CbGbCtD
Dabrafenib—ABCB1—Dexamethasone—rheumatoid arthritis	0.00569	0.00826	CbGbCtD
Dabrafenib—CYP3A4—Hydrocortisone—rheumatoid arthritis	0.00548	0.00796	CbGbCtD
Dabrafenib—CYP3A4—Prednisone—rheumatoid arthritis	0.00546	0.00793	CbGbCtD
Dabrafenib—CYP3A4—Cyclosporine—rheumatoid arthritis	0.00518	0.00752	CbGbCtD
Dabrafenib—ABCB1—Methotrexate—rheumatoid arthritis	0.00457	0.00664	CbGbCtD
Dabrafenib—CYP3A4—Dexamethasone—rheumatoid arthritis	0.00341	0.00495	CbGbCtD
Dabrafenib—LIMK1—tendon—rheumatoid arthritis	0.000392	0.105	CbGeAlD
Dabrafenib—SIK1—parotid gland—rheumatoid arthritis	0.000335	0.09	CbGeAlD
Dabrafenib—SIK1—saliva-secreting gland—rheumatoid arthritis	0.000321	0.0862	CbGeAlD
Dabrafenib—SIK1—connective tissue—rheumatoid arthritis	0.000295	0.0792	CbGeAlD
Dabrafenib—RAF1—parotid gland—rheumatoid arthritis	0.000267	0.0716	CbGeAlD
Dabrafenib—RAF1—saliva-secreting gland—rheumatoid arthritis	0.000255	0.0686	CbGeAlD
Dabrafenib—BRAF—tendon—rheumatoid arthritis	0.000242	0.065	CbGeAlD
Dabrafenib—RAF1—connective tissue—rheumatoid arthritis	0.000235	0.063	CbGeAlD
Dabrafenib—SIK1—lymphoid tissue—rheumatoid arthritis	0.000216	0.0579	CbGeAlD
Dabrafenib—SIK1—tendon—rheumatoid arthritis	0.000203	0.0544	CbGeAlD
Dabrafenib—RAF1—lymphoid tissue—rheumatoid arthritis	0.000172	0.0461	CbGeAlD
Dabrafenib—RAF1—digestive system—rheumatoid arthritis	0.000169	0.0455	CbGeAlD
Dabrafenib—RAF1—tendon—rheumatoid arthritis	0.000161	0.0433	CbGeAlD
Dabrafenib—Pruritus—Leflunomide—rheumatoid arthritis	0.000139	0.000914	CcSEcCtD
Dabrafenib—Connective tissue disorder—Prednisone—rheumatoid arthritis	0.000139	0.000912	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Cyclosporine—rheumatoid arthritis	0.000138	0.000908	CcSEcCtD
Dabrafenib—Oedema—Prednisolone—rheumatoid arthritis	0.000138	0.000907	CcSEcCtD
Dabrafenib—Neutropenia—Methotrexate—rheumatoid arthritis	0.000138	0.000906	CcSEcCtD
Dabrafenib—Dizziness—Azathioprine—rheumatoid arthritis	0.000137	0.000904	CcSEcCtD
Dabrafenib—Insomnia—Cyclosporine—rheumatoid arthritis	0.000137	0.000902	CcSEcCtD
Dabrafenib—Cough—Triamcinolone—rheumatoid arthritis	0.000135	0.000892	CcSEcCtD
Dabrafenib—Oedema—Hydrocortisone—rheumatoid arthritis	0.000135	0.000886	CcSEcCtD
Dabrafenib—Diarrhoea—Leflunomide—rheumatoid arthritis	0.000134	0.000884	CcSEcCtD
Dabrafenib—Hypertension—Triamcinolone—rheumatoid arthritis	0.000134	0.000882	CcSEcCtD
Dabrafenib—Hypertension—Methylprednisolone—rheumatoid arthritis	0.000134	0.000881	CcSEcCtD
Dabrafenib—Infection—Hydrocortisone—rheumatoid arthritis	0.000134	0.00088	CcSEcCtD
Dabrafenib—Hyperhidrosis—Prednisolone—rheumatoid arthritis	0.000133	0.000877	CcSEcCtD
Dabrafenib—Myalgia—Triamcinolone—rheumatoid arthritis	0.000132	0.00087	CcSEcCtD
Dabrafenib—Vomiting—Azathioprine—rheumatoid arthritis	0.000132	0.00087	CcSEcCtD
Dabrafenib—Nervous system disorder—Hydrocortisone—rheumatoid arthritis	0.000132	0.000869	CcSEcCtD
Dabrafenib—Myalgia—Methylprednisolone—rheumatoid arthritis	0.000132	0.000868	CcSEcCtD
Dabrafenib—Arthralgia—Methylprednisolone—rheumatoid arthritis	0.000132	0.000868	CcSEcCtD
Dabrafenib—Eye disorder—Prednisone—rheumatoid arthritis	0.000132	0.000867	CcSEcCtD
Dabrafenib—Decreased appetite—Cyclosporine—rheumatoid arthritis	0.000132	0.000867	CcSEcCtD
Dabrafenib—Infestation—Methotrexate—rheumatoid arthritis	0.000131	0.000864	CcSEcCtD
Dabrafenib—Infestation NOS—Methotrexate—rheumatoid arthritis	0.000131	0.000864	CcSEcCtD
Dabrafenib—Rash—Azathioprine—rheumatoid arthritis	0.000131	0.000862	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—rheumatoid arthritis	0.000131	0.000862	CcSEcCtD
Dabrafenib—Dermatitis—Azathioprine—rheumatoid arthritis	0.000131	0.000862	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Cyclosporine—rheumatoid arthritis	0.000131	0.000861	CcSEcCtD
Dabrafenib—Skin disorder—Hydrocortisone—rheumatoid arthritis	0.000131	0.000861	CcSEcCtD
Dabrafenib—Fatigue—Cyclosporine—rheumatoid arthritis	0.000131	0.000859	CcSEcCtD
Dabrafenib—Headache—Azathioprine—rheumatoid arthritis	0.00013	0.000857	CcSEcCtD
Dabrafenib—Hyperhidrosis—Hydrocortisone—rheumatoid arthritis	0.00013	0.000856	CcSEcCtD
Dabrafenib—Dizziness—Leflunomide—rheumatoid arthritis	0.00013	0.000854	CcSEcCtD
Dabrafenib—Constipation—Cyclosporine—rheumatoid arthritis	0.00013	0.000852	CcSEcCtD
Dabrafenib—Dry mouth—Triamcinolone—rheumatoid arthritis	0.000129	0.000851	CcSEcCtD
Dabrafenib—Renal failure—Methotrexate—rheumatoid arthritis	0.000129	0.000849	CcSEcCtD
Dabrafenib—Stomatitis—Methotrexate—rheumatoid arthritis	0.000128	0.000842	CcSEcCtD
Dabrafenib—Angiopathy—Prednisone—rheumatoid arthritis	0.000128	0.000842	CcSEcCtD
Dabrafenib—Immune system disorder—Prednisone—rheumatoid arthritis	0.000127	0.000838	CcSEcCtD
Dabrafenib—SLCO1B1—digestive system—rheumatoid arthritis	0.000127	0.0341	CbGeAlD
Dabrafenib—Oedema—Triamcinolone—rheumatoid arthritis	0.000127	0.000834	CcSEcCtD
Dabrafenib—Arrhythmia—Prednisone—rheumatoid arthritis	0.000126	0.000829	CcSEcCtD
Dabrafenib—Infection—Triamcinolone—rheumatoid arthritis	0.000126	0.000829	CcSEcCtD
Dabrafenib—Hypotension—Hydrocortisone—rheumatoid arthritis	0.000126	0.000828	CcSEcCtD
Dabrafenib—Infection—Methylprednisolone—rheumatoid arthritis	0.000126	0.000827	CcSEcCtD
Dabrafenib—Haematuria—Methotrexate—rheumatoid arthritis	0.000125	0.000824	CcSEcCtD
Dabrafenib—Vomiting—Leflunomide—rheumatoid arthritis	0.000125	0.000821	CcSEcCtD
Dabrafenib—Insomnia—Prednisolone—rheumatoid arthritis	0.000125	0.00082	CcSEcCtD
Dabrafenib—Alopecia—Prednisone—rheumatoid arthritis	0.000125	0.00082	CcSEcCtD
Dabrafenib—Nervous system disorder—Methylprednisolone—rheumatoid arthritis	0.000124	0.000816	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Cyclosporine—rheumatoid arthritis	0.000124	0.000815	CcSEcCtD
Dabrafenib—Epistaxis—Methotrexate—rheumatoid arthritis	0.000124	0.000815	CcSEcCtD
Dabrafenib—Rash—Leflunomide—rheumatoid arthritis	0.000124	0.000814	CcSEcCtD
Dabrafenib—Dermatitis—Leflunomide—rheumatoid arthritis	0.000124	0.000814	CcSEcCtD
Dabrafenib—Mental disorder—Prednisone—rheumatoid arthritis	0.000123	0.000813	CcSEcCtD
Dabrafenib—Nausea—Azathioprine—rheumatoid arthritis	0.000123	0.000812	CcSEcCtD
Dabrafenib—Headache—Leflunomide—rheumatoid arthritis	0.000123	0.000809	CcSEcCtD
Dabrafenib—Skin disorder—Methylprednisolone—rheumatoid arthritis	0.000123	0.000808	CcSEcCtD
Dabrafenib—Malnutrition—Prednisone—rheumatoid arthritis	0.000123	0.000808	CcSEcCtD
Dabrafenib—Erythema—Prednisone—rheumatoid arthritis	0.000123	0.000808	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Hydrocortisone—rheumatoid arthritis	0.000123	0.000807	CcSEcCtD
Dabrafenib—Hyperhidrosis—Triamcinolone—rheumatoid arthritis	0.000123	0.000806	CcSEcCtD
Dabrafenib—Hyperhidrosis—Methylprednisolone—rheumatoid arthritis	0.000122	0.000805	CcSEcCtD
Dabrafenib—Insomnia—Hydrocortisone—rheumatoid arthritis	0.000122	0.000801	CcSEcCtD
Dabrafenib—Hypertension—Betamethasone—rheumatoid arthritis	0.000122	0.000801	CcSEcCtD
Dabrafenib—Hypertension—Dexamethasone—rheumatoid arthritis	0.000122	0.000801	CcSEcCtD
Dabrafenib—Myalgia—Betamethasone—rheumatoid arthritis	0.00012	0.00079	CcSEcCtD
Dabrafenib—Myalgia—Dexamethasone—rheumatoid arthritis	0.00012	0.00079	CcSEcCtD
Dabrafenib—Abdominal pain—Cyclosporine—rheumatoid arthritis	0.00012	0.000788	CcSEcCtD
Dabrafenib—Body temperature increased—Cyclosporine—rheumatoid arthritis	0.00012	0.000788	CcSEcCtD
Dabrafenib—Haemoglobin—Methotrexate—rheumatoid arthritis	0.000118	0.000779	CcSEcCtD
Dabrafenib—Hypotension—Methylprednisolone—rheumatoid arthritis	0.000118	0.000778	CcSEcCtD
Dabrafenib—Haemorrhage—Methotrexate—rheumatoid arthritis	0.000118	0.000775	CcSEcCtD
Dabrafenib—Decreased appetite—Hydrocortisone—rheumatoid arthritis	0.000117	0.00077	CcSEcCtD
Dabrafenib—Nausea—Leflunomide—rheumatoid arthritis	0.000117	0.000767	CcSEcCtD
Dabrafenib—Urinary tract disorder—Methotrexate—rheumatoid arthritis	0.000116	0.000766	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Hydrocortisone—rheumatoid arthritis	0.000116	0.000765	CcSEcCtD
Dabrafenib—Fatigue—Hydrocortisone—rheumatoid arthritis	0.000116	0.000764	CcSEcCtD
Dabrafenib—Vision blurred—Prednisone—rheumatoid arthritis	0.000116	0.000761	CcSEcCtD
Dabrafenib—Urethral disorder—Methotrexate—rheumatoid arthritis	0.000115	0.00076	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Triamcinolone—rheumatoid arthritis	0.000115	0.00076	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Methylprednisolone—rheumatoid arthritis	0.000115	0.000758	CcSEcCtD
Dabrafenib—Oedema—Betamethasone—rheumatoid arthritis	0.000115	0.000757	CcSEcCtD
Dabrafenib—Oedema—Dexamethasone—rheumatoid arthritis	0.000115	0.000757	CcSEcCtD
Dabrafenib—Insomnia—Triamcinolone—rheumatoid arthritis	0.000115	0.000755	CcSEcCtD
Dabrafenib—Insomnia—Methylprednisolone—rheumatoid arthritis	0.000114	0.000753	CcSEcCtD
Dabrafenib—Infection—Betamethasone—rheumatoid arthritis	0.000114	0.000752	CcSEcCtD
Dabrafenib—Infection—Dexamethasone—rheumatoid arthritis	0.000114	0.000752	CcSEcCtD
Dabrafenib—Anaemia—Prednisone—rheumatoid arthritis	0.000113	0.000747	CcSEcCtD
Dabrafenib—Nervous system disorder—Dexamethasone—rheumatoid arthritis	0.000113	0.000742	CcSEcCtD
Dabrafenib—Nervous system disorder—Betamethasone—rheumatoid arthritis	0.000113	0.000742	CcSEcCtD
Dabrafenib—Thrombocytopenia—Dexamethasone—rheumatoid arthritis	0.000113	0.000741	CcSEcCtD
Dabrafenib—Thrombocytopenia—Betamethasone—rheumatoid arthritis	0.000113	0.000741	CcSEcCtD
Dabrafenib—Hypersensitivity—Cyclosporine—rheumatoid arthritis	0.000112	0.000734	CcSEcCtD
Dabrafenib—Hyperhidrosis—Dexamethasone—rheumatoid arthritis	0.000111	0.000732	CcSEcCtD
Dabrafenib—Hyperhidrosis—Betamethasone—rheumatoid arthritis	0.000111	0.000732	CcSEcCtD
Dabrafenib—ABCG2—parotid gland—rheumatoid arthritis	0.00011	0.0296	CbGeAlD
Dabrafenib—Eye disorder—Methotrexate—rheumatoid arthritis	0.00011	0.000725	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Hydrocortisone—rheumatoid arthritis	0.00011	0.000724	CcSEcCtD
Dabrafenib—Fatigue—Triamcinolone—rheumatoid arthritis	0.000109	0.000719	CcSEcCtD
Dabrafenib—Fatigue—Methylprednisolone—rheumatoid arthritis	0.000109	0.000718	CcSEcCtD
Dabrafenib—Asthenia—Cyclosporine—rheumatoid arthritis	0.000109	0.000715	CcSEcCtD
Dabrafenib—Hypotension—Betamethasone—rheumatoid arthritis	0.000107	0.000707	CcSEcCtD
Dabrafenib—Hypotension—Dexamethasone—rheumatoid arthritis	0.000107	0.000707	CcSEcCtD
Dabrafenib—Pruritus—Cyclosporine—rheumatoid arthritis	0.000107	0.000705	CcSEcCtD
Dabrafenib—Angiopathy—Methotrexate—rheumatoid arthritis	0.000107	0.000704	CcSEcCtD
Dabrafenib—Immune system disorder—Methotrexate—rheumatoid arthritis	0.000106	0.0007	CcSEcCtD
Dabrafenib—Abdominal pain—Hydrocortisone—rheumatoid arthritis	0.000106	0.0007	CcSEcCtD
Dabrafenib—Body temperature increased—Hydrocortisone—rheumatoid arthritis	0.000106	0.0007	CcSEcCtD
Dabrafenib—Mediastinal disorder—Methotrexate—rheumatoid arthritis	0.000106	0.000699	CcSEcCtD
Dabrafenib—Hypertension—Prednisone—rheumatoid arthritis	0.000106	0.000697	CcSEcCtD
Dabrafenib—Chills—Methotrexate—rheumatoid arthritis	0.000106	0.000696	CcSEcCtD
Dabrafenib—ABCG2—saliva-secreting gland—rheumatoid arthritis	0.000106	0.0284	CbGeAlD
Dabrafenib—Musculoskeletal discomfort—Dexamethasone—rheumatoid arthritis	0.000105	0.00069	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Betamethasone—rheumatoid arthritis	0.000105	0.00069	CcSEcCtD
Dabrafenib—Myalgia—Prednisone—rheumatoid arthritis	0.000104	0.000688	CcSEcCtD
Dabrafenib—Arthralgia—Prednisone—rheumatoid arthritis	0.000104	0.000688	CcSEcCtD
Dabrafenib—Alopecia—Methotrexate—rheumatoid arthritis	0.000104	0.000685	CcSEcCtD
Dabrafenib—Insomnia—Betamethasone—rheumatoid arthritis	0.000104	0.000685	CcSEcCtD
Dabrafenib—Insomnia—Dexamethasone—rheumatoid arthritis	0.000104	0.000685	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—rheumatoid arthritis	0.000104	0.000683	CcSEcCtD
Dabrafenib—Diarrhoea—Cyclosporine—rheumatoid arthritis	0.000104	0.000682	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Methylprednisolone—rheumatoid arthritis	0.000103	0.000681	CcSEcCtD
Dabrafenib—Mental disorder—Methotrexate—rheumatoid arthritis	0.000103	0.000679	CcSEcCtD
Dabrafenib—Malnutrition—Methotrexate—rheumatoid arthritis	0.000103	0.000675	CcSEcCtD
Dabrafenib—Erythema—Methotrexate—rheumatoid arthritis	0.000103	0.000675	CcSEcCtD
Dabrafenib—Hypersensitivity—Prednisolone—rheumatoid arthritis	0.000102	0.000668	CcSEcCtD
Dabrafenib—Body temperature increased—Triamcinolone—rheumatoid arthritis	0.0001	0.000659	CcSEcCtD
Dabrafenib—Dizziness—Cyclosporine—rheumatoid arthritis	0.0001	0.000659	CcSEcCtD
Dabrafenib—Oedema—Prednisone—rheumatoid arthritis	0.0001	0.000659	CcSEcCtD
Dabrafenib—Abdominal pain—Methylprednisolone—rheumatoid arthritis	0.0001	0.000658	CcSEcCtD
Dabrafenib—Decreased appetite—Betamethasone—rheumatoid arthritis	0.0001	0.000658	CcSEcCtD
Dabrafenib—Decreased appetite—Dexamethasone—rheumatoid arthritis	0.0001	0.000658	CcSEcCtD
Dabrafenib—Infection—Prednisone—rheumatoid arthritis	9.95e-05	0.000655	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Betamethasone—rheumatoid arthritis	9.93e-05	0.000653	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Dexamethasone—rheumatoid arthritis	9.93e-05	0.000653	CcSEcCtD
Dabrafenib—Back pain—Methotrexate—rheumatoid arthritis	9.92e-05	0.000653	CcSEcCtD
Dabrafenib—Hypersensitivity—Hydrocortisone—rheumatoid arthritis	9.92e-05	0.000653	CcSEcCtD
Dabrafenib—Fatigue—Dexamethasone—rheumatoid arthritis	9.91e-05	0.000653	CcSEcCtD
Dabrafenib—Fatigue—Betamethasone—rheumatoid arthritis	9.91e-05	0.000653	CcSEcCtD
Dabrafenib—Nervous system disorder—Prednisone—rheumatoid arthritis	9.82e-05	0.000646	CcSEcCtD
Dabrafenib—Skin disorder—Prednisone—rheumatoid arthritis	9.73e-05	0.00064	CcSEcCtD
Dabrafenib—Hyperhidrosis—Prednisone—rheumatoid arthritis	9.68e-05	0.000637	CcSEcCtD
Dabrafenib—Vision blurred—Methotrexate—rheumatoid arthritis	9.66e-05	0.000636	CcSEcCtD
Dabrafenib—Asthenia—Hydrocortisone—rheumatoid arthritis	9.66e-05	0.000636	CcSEcCtD
Dabrafenib—Vomiting—Cyclosporine—rheumatoid arthritis	9.63e-05	0.000634	CcSEcCtD
Dabrafenib—Rash—Cyclosporine—rheumatoid arthritis	9.55e-05	0.000629	CcSEcCtD
Dabrafenib—Dermatitis—Cyclosporine—rheumatoid arthritis	9.54e-05	0.000628	CcSEcCtD
Dabrafenib—Pruritus—Hydrocortisone—rheumatoid arthritis	9.52e-05	0.000627	CcSEcCtD
Dabrafenib—Headache—Cyclosporine—rheumatoid arthritis	9.49e-05	0.000625	CcSEcCtD
Dabrafenib—Anaemia—Methotrexate—rheumatoid arthritis	9.48e-05	0.000624	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Betamethasone—rheumatoid arthritis	9.4e-05	0.000619	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Dexamethasone—rheumatoid arthritis	9.4e-05	0.000619	CcSEcCtD
Dabrafenib—Hypersensitivity—Triamcinolone—rheumatoid arthritis	9.34e-05	0.000615	CcSEcCtD
Dabrafenib—Hypersensitivity—Methylprednisolone—rheumatoid arthritis	9.32e-05	0.000613	CcSEcCtD
Dabrafenib—Diarrhoea—Hydrocortisone—rheumatoid arthritis	9.21e-05	0.000606	CcSEcCtD
Dabrafenib—Leukopenia—Methotrexate—rheumatoid arthritis	9.18e-05	0.000604	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Prednisone—rheumatoid arthritis	9.12e-05	0.000601	CcSEcCtD
Dabrafenib—Dizziness—Prednisolone—rheumatoid arthritis	9.11e-05	0.0006	CcSEcCtD
Dabrafenib—Asthenia—Triamcinolone—rheumatoid arthritis	9.09e-05	0.000599	CcSEcCtD
Dabrafenib—Abdominal pain—Betamethasone—rheumatoid arthritis	9.09e-05	0.000598	CcSEcCtD
Dabrafenib—Abdominal pain—Dexamethasone—rheumatoid arthritis	9.09e-05	0.000598	CcSEcCtD
Dabrafenib—Body temperature increased—Betamethasone—rheumatoid arthritis	9.09e-05	0.000598	CcSEcCtD
Dabrafenib—Body temperature increased—Dexamethasone—rheumatoid arthritis	9.09e-05	0.000598	CcSEcCtD
Dabrafenib—Asthenia—Methylprednisolone—rheumatoid arthritis	9.07e-05	0.000597	CcSEcCtD
Dabrafenib—Insomnia—Prednisone—rheumatoid arthritis	9.06e-05	0.000596	CcSEcCtD
Dabrafenib—Nausea—Cyclosporine—rheumatoid arthritis	9e-05	0.000592	CcSEcCtD
Dabrafenib—Pruritus—Triamcinolone—rheumatoid arthritis	8.97e-05	0.00059	CcSEcCtD
Dabrafenib—Cough—Methotrexate—rheumatoid arthritis	8.95e-05	0.000589	CcSEcCtD
Dabrafenib—Pruritus—Methylprednisolone—rheumatoid arthritis	8.95e-05	0.000589	CcSEcCtD
Dabrafenib—Dizziness—Hydrocortisone—rheumatoid arthritis	8.9e-05	0.000586	CcSEcCtD
Dabrafenib—Arthralgia—Methotrexate—rheumatoid arthritis	8.73e-05	0.000575	CcSEcCtD
Dabrafenib—Myalgia—Methotrexate—rheumatoid arthritis	8.73e-05	0.000575	CcSEcCtD
Dabrafenib—Decreased appetite—Prednisone—rheumatoid arthritis	8.7e-05	0.000573	CcSEcCtD
Dabrafenib—Rash—Prednisolone—rheumatoid arthritis	8.69e-05	0.000572	CcSEcCtD
Dabrafenib—Dermatitis—Prednisolone—rheumatoid arthritis	8.68e-05	0.000571	CcSEcCtD
Dabrafenib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—rheumatoid arthritis	8.67e-05	0.000571	CcSEcCtD
Dabrafenib—Diarrhoea—Methylprednisolone—rheumatoid arthritis	8.65e-05	0.00057	CcSEcCtD
Dabrafenib—Fatigue—Prednisone—rheumatoid arthritis	8.63e-05	0.000568	CcSEcCtD
Dabrafenib—Headache—Prednisolone—rheumatoid arthritis	8.63e-05	0.000568	CcSEcCtD
Dabrafenib—Constipation—Prednisone—rheumatoid arthritis	8.56e-05	0.000564	CcSEcCtD
Dabrafenib—Vomiting—Hydrocortisone—rheumatoid arthritis	8.56e-05	0.000563	CcSEcCtD
Dabrafenib—Rash—Hydrocortisone—rheumatoid arthritis	8.49e-05	0.000559	CcSEcCtD
Dabrafenib—Dermatitis—Hydrocortisone—rheumatoid arthritis	8.48e-05	0.000558	CcSEcCtD
Dabrafenib—Headache—Hydrocortisone—rheumatoid arthritis	8.43e-05	0.000555	CcSEcCtD
Dabrafenib—Dizziness—Triamcinolone—rheumatoid arthritis	8.38e-05	0.000552	CcSEcCtD
Dabrafenib—Dizziness—Methylprednisolone—rheumatoid arthritis	8.36e-05	0.00055	CcSEcCtD
Dabrafenib—Infection—Methotrexate—rheumatoid arthritis	8.31e-05	0.000547	CcSEcCtD
Dabrafenib—Asthenia—Betamethasone—rheumatoid arthritis	8.25e-05	0.000543	CcSEcCtD
Dabrafenib—Asthenia—Dexamethasone—rheumatoid arthritis	8.25e-05	0.000543	CcSEcCtD
Dabrafenib—Nervous system disorder—Methotrexate—rheumatoid arthritis	8.21e-05	0.00054	CcSEcCtD
Dabrafenib—Thrombocytopenia—Methotrexate—rheumatoid arthritis	8.19e-05	0.000539	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Prednisone—rheumatoid arthritis	8.19e-05	0.000539	CcSEcCtD
Dabrafenib—Nausea—Prednisolone—rheumatoid arthritis	8.19e-05	0.000539	CcSEcCtD
Dabrafenib—Pruritus—Dexamethasone—rheumatoid arthritis	8.14e-05	0.000536	CcSEcCtD
Dabrafenib—Pruritus—Betamethasone—rheumatoid arthritis	8.14e-05	0.000536	CcSEcCtD
Dabrafenib—Skin disorder—Methotrexate—rheumatoid arthritis	8.13e-05	0.000535	CcSEcCtD
Dabrafenib—Hyperhidrosis—Methotrexate—rheumatoid arthritis	8.09e-05	0.000533	CcSEcCtD
Dabrafenib—Vomiting—Triamcinolone—rheumatoid arthritis	8.06e-05	0.00053	CcSEcCtD
Dabrafenib—Vomiting—Methylprednisolone—rheumatoid arthritis	8.04e-05	0.000529	CcSEcCtD
Dabrafenib—Nausea—Hydrocortisone—rheumatoid arthritis	7.99e-05	0.000526	CcSEcCtD
Dabrafenib—Rash—Triamcinolone—rheumatoid arthritis	7.99e-05	0.000526	CcSEcCtD
Dabrafenib—Dermatitis—Triamcinolone—rheumatoid arthritis	7.98e-05	0.000526	CcSEcCtD
Dabrafenib—Rash—Methylprednisolone—rheumatoid arthritis	7.97e-05	0.000525	CcSEcCtD
Dabrafenib—Dermatitis—Methylprednisolone—rheumatoid arthritis	7.97e-05	0.000524	CcSEcCtD
Dabrafenib—Headache—Triamcinolone—rheumatoid arthritis	7.94e-05	0.000523	CcSEcCtD
Dabrafenib—Headache—Methylprednisolone—rheumatoid arthritis	7.92e-05	0.000521	CcSEcCtD
Dabrafenib—Abdominal pain—Prednisone—rheumatoid arthritis	7.92e-05	0.000521	CcSEcCtD
Dabrafenib—Body temperature increased—Prednisone—rheumatoid arthritis	7.92e-05	0.000521	CcSEcCtD
Dabrafenib—Diarrhoea—Dexamethasone—rheumatoid arthritis	7.87e-05	0.000518	CcSEcCtD
Dabrafenib—Diarrhoea—Betamethasone—rheumatoid arthritis	7.87e-05	0.000518	CcSEcCtD
Dabrafenib—Hypotension—Methotrexate—rheumatoid arthritis	7.82e-05	0.000515	CcSEcCtD
Dabrafenib—Musculoskeletal discomfort—Methotrexate—rheumatoid arthritis	7.62e-05	0.000502	CcSEcCtD
Dabrafenib—Dizziness—Dexamethasone—rheumatoid arthritis	7.6e-05	0.000501	CcSEcCtD
Dabrafenib—Dizziness—Betamethasone—rheumatoid arthritis	7.6e-05	0.000501	CcSEcCtD
Dabrafenib—Insomnia—Methotrexate—rheumatoid arthritis	7.57e-05	0.000498	CcSEcCtD
Dabrafenib—Nausea—Triamcinolone—rheumatoid arthritis	7.53e-05	0.000496	CcSEcCtD
Dabrafenib—Nausea—Methylprednisolone—rheumatoid arthritis	7.51e-05	0.000494	CcSEcCtD
Dabrafenib—Hypersensitivity—Prednisone—rheumatoid arthritis	7.38e-05	0.000486	CcSEcCtD
Dabrafenib—Vomiting—Dexamethasone—rheumatoid arthritis	7.31e-05	0.000481	CcSEcCtD
Dabrafenib—Vomiting—Betamethasone—rheumatoid arthritis	7.31e-05	0.000481	CcSEcCtD
Dabrafenib—Decreased appetite—Methotrexate—rheumatoid arthritis	7.27e-05	0.000479	CcSEcCtD
Dabrafenib—Rash—Dexamethasone—rheumatoid arthritis	7.25e-05	0.000477	CcSEcCtD
Dabrafenib—Rash—Betamethasone—rheumatoid arthritis	7.25e-05	0.000477	CcSEcCtD
Dabrafenib—Dermatitis—Dexamethasone—rheumatoid arthritis	7.24e-05	0.000477	CcSEcCtD
Dabrafenib—Dermatitis—Betamethasone—rheumatoid arthritis	7.24e-05	0.000477	CcSEcCtD
Dabrafenib—Gastrointestinal disorder—Methotrexate—rheumatoid arthritis	7.23e-05	0.000476	CcSEcCtD
Dabrafenib—Fatigue—Methotrexate—rheumatoid arthritis	7.22e-05	0.000475	CcSEcCtD
Dabrafenib—Headache—Dexamethasone—rheumatoid arthritis	7.2e-05	0.000474	CcSEcCtD
Dabrafenib—Headache—Betamethasone—rheumatoid arthritis	7.2e-05	0.000474	CcSEcCtD
Dabrafenib—Asthenia—Prednisone—rheumatoid arthritis	7.18e-05	0.000473	CcSEcCtD
Dabrafenib—Pruritus—Prednisone—rheumatoid arthritis	7.08e-05	0.000466	CcSEcCtD
Dabrafenib—Diarrhoea—Prednisone—rheumatoid arthritis	6.85e-05	0.000451	CcSEcCtD
Dabrafenib—Gastrointestinal pain—Methotrexate—rheumatoid arthritis	6.84e-05	0.00045	CcSEcCtD
Dabrafenib—Nausea—Dexamethasone—rheumatoid arthritis	6.83e-05	0.00045	CcSEcCtD
Dabrafenib—Nausea—Betamethasone—rheumatoid arthritis	6.83e-05	0.00045	CcSEcCtD
Dabrafenib—Dizziness—Prednisone—rheumatoid arthritis	6.62e-05	0.000436	CcSEcCtD
Dabrafenib—Body temperature increased—Methotrexate—rheumatoid arthritis	6.62e-05	0.000435	CcSEcCtD
Dabrafenib—Abdominal pain—Methotrexate—rheumatoid arthritis	6.62e-05	0.000435	CcSEcCtD
Dabrafenib—Vomiting—Prednisone—rheumatoid arthritis	6.37e-05	0.000419	CcSEcCtD
Dabrafenib—Rash—Prednisone—rheumatoid arthritis	6.31e-05	0.000416	CcSEcCtD
Dabrafenib—Dermatitis—Prednisone—rheumatoid arthritis	6.31e-05	0.000415	CcSEcCtD
Dabrafenib—Headache—Prednisone—rheumatoid arthritis	6.27e-05	0.000413	CcSEcCtD
Dabrafenib—Hypersensitivity—Methotrexate—rheumatoid arthritis	6.17e-05	0.000406	CcSEcCtD
Dabrafenib—Asthenia—Methotrexate—rheumatoid arthritis	6e-05	0.000395	CcSEcCtD
Dabrafenib—Nausea—Prednisone—rheumatoid arthritis	5.95e-05	0.000392	CcSEcCtD
Dabrafenib—Pruritus—Methotrexate—rheumatoid arthritis	5.92e-05	0.00039	CcSEcCtD
Dabrafenib—Diarrhoea—Methotrexate—rheumatoid arthritis	5.73e-05	0.000377	CcSEcCtD
Dabrafenib—Dizziness—Methotrexate—rheumatoid arthritis	5.53e-05	0.000364	CcSEcCtD
Dabrafenib—Vomiting—Methotrexate—rheumatoid arthritis	5.32e-05	0.00035	CcSEcCtD
Dabrafenib—Rash—Methotrexate—rheumatoid arthritis	5.28e-05	0.000347	CcSEcCtD
Dabrafenib—Dermatitis—Methotrexate—rheumatoid arthritis	5.27e-05	0.000347	CcSEcCtD
Dabrafenib—Headache—Methotrexate—rheumatoid arthritis	5.24e-05	0.000345	CcSEcCtD
Dabrafenib—Nausea—Methotrexate—rheumatoid arthritis	4.97e-05	0.000327	CcSEcCtD
Dabrafenib—CYP3A4—digestive system—rheumatoid arthritis	4.88e-05	0.0131	CbGeAlD
Dabrafenib—ABCB1—lymphoid tissue—rheumatoid arthritis	3.5e-05	0.0094	CbGeAlD
Dabrafenib—ABCB1—digestive system—rheumatoid arthritis	3.46e-05	0.00929	CbGeAlD
Dabrafenib—RAF1—Signaling Pathways—NFATC1—rheumatoid arthritis	1.36e-05	8.7e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—SYK—rheumatoid arthritis	1.36e-05	8.69e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—ACAN—rheumatoid arthritis	1.36e-05	8.69e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—VCAM1—rheumatoid arthritis	1.34e-05	8.61e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—HLA-DQA1—rheumatoid arthritis	1.34e-05	8.58e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—PRKCQ—rheumatoid arthritis	1.33e-05	8.53e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PLB1—rheumatoid arthritis	1.32e-05	8.48e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—PRKCQ—rheumatoid arthritis	1.32e-05	8.43e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—STAT1—rheumatoid arthritis	1.31e-05	8.38e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—rheumatoid arthritis	1.31e-05	8.38e-05	CbGpPWpGaD
Dabrafenib—SLC22A6—Transmembrane transport of small molecules—ALB—rheumatoid arthritis	1.3e-05	8.35e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—CCL5—rheumatoid arthritis	1.3e-05	8.33e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CCR6—rheumatoid arthritis	1.3e-05	8.32e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—FADS2—rheumatoid arthritis	1.3e-05	8.31e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—STAT1—rheumatoid arthritis	1.29e-05	8.28e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CXCL10—rheumatoid arthritis	1.29e-05	8.26e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—CSF2—rheumatoid arthritis	1.28e-05	8.21e-05	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—TYK2—rheumatoid arthritis	1.28e-05	8.18e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—SLC25A12—rheumatoid arthritis	1.28e-05	8.17e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—ENO1—rheumatoid arthritis	1.27e-05	8.13e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—NCF2—rheumatoid arthritis	1.26e-05	8.09e-05	CbGpPWpGaD
Dabrafenib—RAF1—Transmembrane transport of small molecules—ALB—rheumatoid arthritis	1.26e-05	8.07e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—HLA-DQB1—rheumatoid arthritis	1.25e-05	8.03e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism of lipids and lipoproteins—ALB—rheumatoid arthritis	1.25e-05	7.99e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PTGES—rheumatoid arthritis	1.24e-05	7.95e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—GC—rheumatoid arthritis	1.24e-05	7.95e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—SH2B3—rheumatoid arthritis	1.23e-05	7.89e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TRAF6—rheumatoid arthritis	1.23e-05	7.89e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—GZMB—rheumatoid arthritis	1.22e-05	7.84e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—IL6ST—rheumatoid arthritis	1.22e-05	7.82e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—PTK2—rheumatoid arthritis	1.21e-05	7.76e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—NOS2—rheumatoid arthritis	1.21e-05	7.76e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IL1A—rheumatoid arthritis	1.19e-05	7.63e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IL18—rheumatoid arthritis	1.19e-05	7.61e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CXCL2—rheumatoid arthritis	1.19e-05	7.61e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CCL3—rheumatoid arthritis	1.19e-05	7.61e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Transmembrane transport of small molecules—ALB—rheumatoid arthritis	1.19e-05	7.6e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CD40LG—rheumatoid arthritis	1.18e-05	7.58e-05	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—IL2—rheumatoid arthritis	1.18e-05	7.56e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—MMP3—rheumatoid arthritis	1.18e-05	7.54e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—CD80—rheumatoid arthritis	1.18e-05	7.53e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—ENO1—rheumatoid arthritis	1.17e-05	7.52e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—CCR5—rheumatoid arthritis	1.17e-05	7.51e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CD8A—rheumatoid arthritis	1.17e-05	7.5e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CSF2—rheumatoid arthritis	1.17e-05	7.5e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—SAA1—rheumatoid arthritis	1.16e-05	7.44e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—MED1—rheumatoid arthritis	1.16e-05	7.44e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—IL2RA—rheumatoid arthritis	1.16e-05	7.4e-05	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—CD4—rheumatoid arthritis	1.15e-05	7.39e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PLB1—rheumatoid arthritis	1.15e-05	7.39e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—C3—rheumatoid arthritis	1.15e-05	7.33e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—AGER—rheumatoid arthritis	1.14e-05	7.31e-05	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—MMP9—rheumatoid arthritis	1.14e-05	7.29e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—NCF1—rheumatoid arthritis	1.14e-05	7.29e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—rheumatoid arthritis	1.14e-05	7.27e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—MTHFR—rheumatoid arthritis	1.13e-05	7.27e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—PTK2—rheumatoid arthritis	1.13e-05	7.26e-05	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—NFKB1—rheumatoid arthritis	1.13e-05	7.21e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—HLA-B—rheumatoid arthritis	1.13e-05	7.21e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK8—rheumatoid arthritis	1.12e-05	7.15e-05	CbGpPWpGaD
Dabrafenib—RAF1—Cytokine Signaling in Immune system—IL6—rheumatoid arthritis	1.11e-05	7.13e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CCL5—rheumatoid arthritis	1.11e-05	7.11e-05	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—CD4—rheumatoid arthritis	1.11e-05	7.1e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Biological oxidations—POMC—rheumatoid arthritis	1.1e-05	7.04e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Transmembrane transport of small molecules—ALB—rheumatoid arthritis	1.1e-05	7.04e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by NGF—IL6—rheumatoid arthritis	1.09e-05	7.01e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CD28—rheumatoid arthritis	1.09e-05	7.01e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CSF2—rheumatoid arthritis	1.09e-05	7.01e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—rheumatoid arthritis	1.09e-05	6.99e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—IL6R—rheumatoid arthritis	1.09e-05	6.98e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—ACP5—rheumatoid arthritis	1.08e-05	6.91e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—B3GNT2—rheumatoid arthritis	1.08e-05	6.91e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IL2RA—rheumatoid arthritis	1.06e-05	6.76e-05	CbGpPWpGaD
Dabrafenib—LIMK1—Immune System—IL6—rheumatoid arthritis	1.05e-05	6.73e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—C3—rheumatoid arthritis	1.05e-05	6.7e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—HLA-A—rheumatoid arthritis	1.04e-05	6.68e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—rheumatoid arthritis	1.03e-05	6.6e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—UBE2D1—rheumatoid arthritis	1.03e-05	6.6e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—SPP1—rheumatoid arthritis	1.03e-05	6.59e-05	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—VEGFA—rheumatoid arthritis	1.02e-05	6.55e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—MED1—rheumatoid arthritis	1.01e-05	6.48e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CXCL12—rheumatoid arthritis	1.01e-05	6.47e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—BDKRB2—rheumatoid arthritis	1.01e-05	6.47e-05	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—VEGFA—rheumatoid arthritis	1e-05	6.42e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—IL6ST—rheumatoid arthritis	1e-05	6.41e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CCR5—rheumatoid arthritis	1e-05	6.41e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—ADRBK1—rheumatoid arthritis	9.99e-06	6.4e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CRP—rheumatoid arthritis	9.96e-06	6.38e-05	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—NFKB1—rheumatoid arthritis	9.95e-06	6.37e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—TYK2—rheumatoid arthritis	9.92e-06	6.35e-05	CbGpPWpGaD
Dabrafenib—RAF1—Axon guidance—IL6—rheumatoid arthritis	9.91e-06	6.34e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CCR5—rheumatoid arthritis	9.89e-06	6.33e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—IL2RA—rheumatoid arthritis	9.86e-06	6.32e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—C3—rheumatoid arthritis	9.78e-06	6.26e-05	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—MAPK8—rheumatoid arthritis	9.78e-06	6.26e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—NOS3—rheumatoid arthritis	9.74e-06	6.24e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—BGN—rheumatoid arthritis	9.72e-06	6.22e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—MTHFR—rheumatoid arthritis	9.66e-06	6.19e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—HLA-A—rheumatoid arthritis	9.64e-06	6.17e-05	CbGpPWpGaD
Dabrafenib—RAF1—Adaptive Immune System—NFKB1—rheumatoid arthritis	9.55e-06	6.12e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—TLR4—rheumatoid arthritis	9.54e-06	6.11e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—HLA-DRB1—rheumatoid arthritis	9.53e-06	6.11e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—rheumatoid arthritis	9.46e-06	6.06e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—RASGRP1—rheumatoid arthritis	9.42e-06	6.03e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—B3GNT2—rheumatoid arthritis	9.4e-06	6.02e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—ACP5—rheumatoid arthritis	9.4e-06	6.02e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—SYK—rheumatoid arthritis	9.39e-06	6.01e-05	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—TGFB1—rheumatoid arthritis	9.38e-06	6.01e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PRKCQ—rheumatoid arthritis	9.22e-06	5.9e-05	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—TGFB1—rheumatoid arthritis	9.2e-06	5.89e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—POMC—rheumatoid arthritis	9.16e-06	5.87e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IL6ST—rheumatoid arthritis	9.15e-06	5.86e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—ICAM1—rheumatoid arthritis	9.15e-06	5.86e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—CAT—rheumatoid arthritis	9.13e-06	5.85e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—LEP—rheumatoid arthritis	9.1e-06	5.83e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—POMC—rheumatoid arthritis	9.07e-06	5.81e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—STAT1—rheumatoid arthritis	9.06e-06	5.8e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—CD4—rheumatoid arthritis	8.97e-06	5.75e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—CCL2—rheumatoid arthritis	8.96e-06	5.74e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—ALOX5—rheumatoid arthritis	8.94e-06	5.73e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—IL6R—rheumatoid arthritis	8.94e-06	5.72e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CXCL10—rheumatoid arthritis	8.93e-06	5.72e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—PTGS2—rheumatoid arthritis	8.91e-06	5.7e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—rheumatoid arthritis	8.84e-06	5.66e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CD80—rheumatoid arthritis	8.81e-06	5.64e-05	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—TNF—rheumatoid arthritis	8.76e-06	5.61e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PLD4—rheumatoid arthritis	8.65e-06	5.54e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—FN1—rheumatoid arthritis	8.59e-06	5.5e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—IL6ST—rheumatoid arthritis	8.55e-06	5.48e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—BGN—rheumatoid arthritis	8.47e-06	5.42e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—CAT—rheumatoid arthritis	8.46e-06	5.42e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—IL6ST—rheumatoid arthritis	8.45e-06	5.41e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—NOS2—rheumatoid arthritis	8.38e-06	5.37e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ACAN—rheumatoid arthritis	8.36e-06	5.35e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—ALB—rheumatoid arthritis	8.27e-06	5.3e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CD80—rheumatoid arthritis	8.23e-06	5.27e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IL6R—rheumatoid arthritis	8.16e-06	5.23e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MMP3—rheumatoid arthritis	8.14e-06	5.21e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—TYK2—rheumatoid arthritis	8.14e-06	5.21e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CD80—rheumatoid arthritis	8.13e-06	5.21e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—NOS3—rheumatoid arthritis	7.91e-06	5.07e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—POMC—rheumatoid arthritis	7.87e-06	5.04e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—SLC25A12—rheumatoid arthritis	7.86e-06	5.03e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—PTK2—rheumatoid arthritis	7.84e-06	5.02e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—POMC—rheumatoid arthritis	7.82e-06	5.01e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—ALOX5—rheumatoid arthritis	7.79e-06	4.99e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—rheumatoid arthritis	7.79e-06	4.99e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CCL5—rheumatoid arthritis	7.69e-06	4.92e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CCL2—rheumatoid arthritis	7.65e-06	4.9e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—GC—rheumatoid arthritis	7.64e-06	4.9e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PTGES—rheumatoid arthritis	7.64e-06	4.9e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—IL6R—rheumatoid arthritis	7.63e-06	4.89e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—MTHFR—rheumatoid arthritis	7.62e-06	4.88e-05	CbGpPWpGaD
Dabrafenib—RAF1—Hemostasis—TP53—rheumatoid arthritis	7.58e-06	4.85e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CSF2—rheumatoid arthritis	7.57e-06	4.85e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—IL6R—rheumatoid arthritis	7.54e-06	4.83e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—TYK2—rheumatoid arthritis	7.44e-06	4.76e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—ENO1—rheumatoid arthritis	7.29e-06	4.67e-05	CbGpPWpGaD
Dabrafenib—SLCO1B3—Metabolism—PTGS2—rheumatoid arthritis	7.24e-06	4.63e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—ALB—rheumatoid arthritis	7.17e-06	4.59e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—SPP1—rheumatoid arthritis	7.12e-06	4.56e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PLB1—rheumatoid arthritis	7.11e-06	4.55e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—CXCL8—rheumatoid arthritis	7.09e-06	4.54e-05	CbGpPWpGaD
Dabrafenib—RAF1—Developmental Biology—IL6—rheumatoid arthritis	7.07e-06	4.53e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—MTHFR—rheumatoid arthritis	7.06e-06	4.52e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IFNG—rheumatoid arthritis	6.96e-06	4.46e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—TYK2—rheumatoid arthritis	6.95e-06	4.45e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CCR5—rheumatoid arthritis	6.92e-06	4.43e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—TYK2—rheumatoid arthritis	6.87e-06	4.4e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IL2RA—rheumatoid arthritis	6.82e-06	4.37e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—NOS3—rheumatoid arthritis	6.82e-06	4.37e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—IL2—rheumatoid arthritis	6.77e-06	4.34e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—C3—rheumatoid arthritis	6.77e-06	4.33e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—NOS3—rheumatoid arthritis	6.74e-06	4.32e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—CD4—rheumatoid arthritis	6.72e-06	4.31e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—TGFB1—rheumatoid arthritis	6.44e-06	4.12e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—ENO1—rheumatoid arthritis	6.35e-06	4.07e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—LEP—rheumatoid arthritis	6.3e-06	4.03e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—rheumatoid arthritis	6.27e-06	4.02e-05	CbGpPWpGaD
Dabrafenib—RAF1—Innate Immune System—IL6—rheumatoid arthritis	6.24e-06	4e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—MED1—rheumatoid arthritis	6.23e-06	3.99e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IL1B—rheumatoid arthritis	6.21e-06	3.98e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—CD4—rheumatoid arthritis	6.21e-06	3.98e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IL2—rheumatoid arthritis	6.19e-06	3.96e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—PTGS2—rheumatoid arthritis	6.16e-06	3.95e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—POMC—rheumatoid arthritis	6.1e-06	3.9e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—CXCL8—rheumatoid arthritis	6.05e-06	3.87e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Transmembrane transport of small molecules—ALB—rheumatoid arthritis	5.94e-06	3.8e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—FN1—rheumatoid arthritis	5.94e-06	3.8e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IL6ST—rheumatoid arthritis	5.92e-06	3.79e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—NFKB1—rheumatoid arthritis	5.79e-06	3.71e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—B3GNT2—rheumatoid arthritis	5.79e-06	3.71e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ACP5—rheumatoid arthritis	5.79e-06	3.71e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—IL2—rheumatoid arthritis	5.78e-06	3.7e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—MAPK8—rheumatoid arthritis	5.7e-06	3.65e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CD80—rheumatoid arthritis	5.7e-06	3.65e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—POMC—rheumatoid arthritis	5.64e-06	3.61e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—ALB—rheumatoid arthritis	5.56e-06	3.56e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—MMP9—rheumatoid arthritis	5.47e-06	3.5e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—NFKB1—rheumatoid arthritis	5.41e-06	3.47e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—POMC—rheumatoid arthritis	5.41e-06	3.47e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—MAPK8—rheumatoid arthritis	5.32e-06	3.41e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—NOS3—rheumatoid arthritis	5.32e-06	3.4e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CCL2—rheumatoid arthritis	5.29e-06	3.39e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IL6R—rheumatoid arthritis	5.28e-06	3.38e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—CAT—rheumatoid arthritis	5.25e-06	3.36e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—BGN—rheumatoid arthritis	5.22e-06	3.34e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—ALB—rheumatoid arthritis	5.15e-06	3.3e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—NOS3—rheumatoid arthritis	4.92e-06	3.15e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—VEGFA—rheumatoid arthritis	4.91e-06	3.15e-05	CbGpPWpGaD
Dabrafenib—SLCO1B1—Metabolism—PTGS2—rheumatoid arthritis	4.86e-06	3.11e-05	CbGpPWpGaD
Dabrafenib—BRAF—Disease—IL6—rheumatoid arthritis	4.85e-06	3.11e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TYK2—rheumatoid arthritis	4.81e-06	3.08e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ALOX5—rheumatoid arthritis	4.8e-06	3.07e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—NOS3—rheumatoid arthritis	4.72e-06	3.02e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—CAT—rheumatoid arthritis	4.57e-06	2.93e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—TGFB1—rheumatoid arthritis	4.51e-06	2.89e-05	CbGpPWpGaD
Dabrafenib—ABCG2—Metabolism—PTGS2—rheumatoid arthritis	4.5e-06	2.88e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—TGFB1—rheumatoid arthritis	4.46e-06	2.85e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—MTHFR—rheumatoid arthritis	4.38e-06	2.8e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—CXCL8—rheumatoid arthritis	4.19e-06	2.68e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IL2—rheumatoid arthritis	4e-06	2.56e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling by GPCR—IL6—rheumatoid arthritis	3.98e-06	2.55e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ENO1—rheumatoid arthritis	3.91e-06	2.51e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—MTHFR—rheumatoid arthritis	3.82e-06	2.44e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MMP9—rheumatoid arthritis	3.79e-06	2.42e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—NFKB1—rheumatoid arthritis	3.75e-06	2.4e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—TP53—rheumatoid arthritis	3.71e-06	2.38e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—MAPK8—rheumatoid arthritis	3.68e-06	2.36e-05	CbGpPWpGaD
Dabrafenib—RAF1—Immune System—IL6—rheumatoid arthritis	3.64e-06	2.33e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—POMC—rheumatoid arthritis	3.5e-06	2.24e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—VEGFA—rheumatoid arthritis	3.4e-06	2.18e-05	CbGpPWpGaD
Dabrafenib—BRAF—Signaling Pathways—IL6—rheumatoid arthritis	3.4e-06	2.18e-05	CbGpPWpGaD
Dabrafenib—RAF1—Disease—IL6—rheumatoid arthritis	3.36e-06	2.15e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—ALB—rheumatoid arthritis	3.19e-06	2.05e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TGFB1—rheumatoid arthritis	3.12e-06	2e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—NOS3—rheumatoid arthritis	3.05e-06	1.96e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—POMC—rheumatoid arthritis	3.05e-06	1.95e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—CAT—rheumatoid arthritis	2.82e-06	1.8e-05	CbGpPWpGaD
Dabrafenib—CYP2C8—Metabolism—PTGS2—rheumatoid arthritis	2.79e-06	1.79e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—ALB—rheumatoid arthritis	2.78e-06	1.78e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—NOS3—rheumatoid arthritis	2.66e-06	1.7e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—TP53—rheumatoid arthritis	2.57e-06	1.65e-05	CbGpPWpGaD
Dabrafenib—ABCB1—Metabolism—PTGS2—rheumatoid arthritis	2.43e-06	1.56e-05	CbGpPWpGaD
Dabrafenib—RAF1—Signaling Pathways—IL6—rheumatoid arthritis	2.35e-06	1.51e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—MTHFR—rheumatoid arthritis	2.35e-06	1.51e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—POMC—rheumatoid arthritis	1.88e-06	1.2e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—ALB—rheumatoid arthritis	1.71e-06	1.1e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—NOS3—rheumatoid arthritis	1.64e-06	1.05e-05	CbGpPWpGaD
Dabrafenib—CYP3A4—Metabolism—PTGS2—rheumatoid arthritis	1.5e-06	9.6e-06	CbGpPWpGaD
